EDITORIAL

Utility of serological markers in inflammatory bowel diseases: Gadget or magic?

Maria Papp, Gary L Norman, Istvan Altorjay, Peter Laszlo Lakatos

Maria Papp, Istvan Altorjay, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary
Gary L Norman, INOVA Diagnostics, Inc. San Diego, United States
Peter Laszlo Lakatos, 1st Department of Medicine, Semmelweis University, Budapest, Hungary
Supported by Mecenatúra (11/2005) grant
Correspondence to: Peter Laszlo Lakatos, MD, PhD, 1st Department of Medicine, Semmelweis University, Koranyi str. 2/A H-1083, Hungary. kislakpet@bel1.sote.hu
Telephone: +36-1-2100278-1500 Fax: +36-1-3130250
Received: 2007-02-06   Accepted: 2007-03-12

Abstract

The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-*Saccharomyces cerevisiae* antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.

Key words: Serologic markers; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Indeterminate colitis; Antineutrophil cytoplasmic antibodies; Anti-Saccharomyces cerevisiae mannan antibodies; Outer membrane porin

http://www.wjgnet.com/1007-9327/13/2028.asp

INTRODUCTION

Serologic response to various microbial and autoantigens can develop in inflammatory bowel diseases (IBD). In addition to the well-established atypical perinuclear antineutrophil cytoplasmic antibodies (atypical P-ANCA) and anti-*Saccharomyces cerevisiae* mannan antibodies (ASCA), a number of new antibodies have recently been discovered and data on their clinical significance has been rapidly increasing.

The usefulness of different antibodies in Crohn's disease (CD) and ulcerative colitis (UC) as diagnostic markers, follow-up parameters, or as subclinical markers in affected families has been actively investigated. Another field of interest is the association of the serologic markers with the disease phenotype, disease course, and treatment stratification. The role of the antibodies in disease pathophysiology remains to be fully elucidated.

In this review we discuss current understanding of the clinical importance of various established and newly recognized serologic markers in IBD.

SEROLOGIC PANEL FOR INFLAMMATORY BOWEL DISEASE

Anti-neutrophil cytoplasmic antibody

The classic anti-neutrophil cytoplasmic antibody (ANCA) tests are used to diagnose and monitor the inflammatory activity in primary small vessel vasculitides. On the basis of an international consensus statement, ANCA testing is performed with serum samples by indirect immunofluorescence (IIF) on normal peripheral blood neutrophils. Two basic ANCA patterns are detectable: the cytoplasmic (C-ANCA) and the perinuclear (P-ANCA). The C-ANCA pattern appears as a granular, diffuse cytoplasmic fluorescence, often with accentuated fluorescence around the nuclear lobes. Typical P-ANCA reactivity results in homogeneous rim-like staining of the perinuclear cytoplasm. ANCA positive serum samples and also those with any other cytoplasmic fluorescence or an antinuclear antibody (ANA) that results in homogeneous or peripheral nuclear fluorescence should be tested in enzyme-linked immunosorbent assays (ELISA) for proteinase 3 (PR3) and myeloperoxidase (MPO)

antibodies, because these are the most common targets of C-ANCA and P-ANCA antibodies respectively (Minimum recommendation of consensus group). Ideally, ELISAs should be performed on all serum samples, since IIF alone detects only 90% to 95% of all ANCA positive serum samples in patients[1]. A third ANCA pattern of clinical importance is the so-called atypical P-ANCA staining. It has been suggested that since the target antigens of atypical P-ANCA are nuclear rather than cytoplasmic, this pattern would be more properly named anti-neutrophil nuclear antigen (ANNA). Until the target of atypical P-ANCA reactivity is identified however, it is likely that the atypical nomenclature will remain in common use. Atypical P-ANCA is recognized as a broad inhomogeneous rim-like staining of the nuclear periphery often with multiple intranuclear foci[2]. The antigen specificity of these atypical ANCAs are different from the classic C- and P-ANCAs, being localized in the nuclear periphery, in contrast to the cytoplasmic location of the classic C- and P-ANCAs. Atypical P-ANCAs are most commonly seen in patients with IBD, especially ulcerative colitis, and some autoimmune liver diseases such as autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC).

Atypical P-ANCA is present in the sera of 40% to 80% of patients with UC[3,4] and to a lesser extent in CD (5%-25%)[5]. The prevalence of the antibody is also high in patients with PSC (88%)[6] and AIH type I (81%)[7], but is detected in only 1%-3% of healthy control subjects. Some sera with atypical ANCA reactivity are positive for antibodies to elastase, lactoferrin, cathepsin G, lysosyme or bactericidal permeability-increasing protein (BPI), but since they are only detected in a few atypical P-ANCA positive sera, these antigens do not appear to be the primary targets of atypical P-ANCA reactivity.

The target antigen(s) of atypical P-ANCA have not been definitively identified. What is in agreement is that target antigen(s) are associated with inner side of the neutrophil nuclear membrane. A 50-kilodalton myeloid-specific protein has been identified by Tejung and appears to be the best current candidate as the primary target of atypical P-ANCA. Histone H1, which binds to the DNA linking nucleosomes, has been suggested as a target antigen of atypical P-ANCA[8]. However, histone H1 is found in all cells with nucleus and is not specific to neutrophils. There has been little independent support of this idea.

Differentiation of the atypical P-ANCA from the typical vasculitis P-ANCA pattern is difficult on ethanol-fixed neutrophils. The patterns are most reliably differentiated by testing sera on both ethanol and formalin-fixed neutrophil slides. The typical P-ANCA pattern converts to a cytoplasmic C-ANCA pattern when tested on formalin-fixed neutrophils, while atypical P-ANCA is mostly destroyed by the formalin treatment or presents weak homogeneous staining[9]. Despite the above-mentioned differences, IBD (and autoimmune liver disease)-associated atypical P-ANCA is still often only referred to as P-ANCA. This failure to clearly distinguish P-ANCA reactivity from atypical P-ANCA reactivity can lead to considerable confusion and should be highly discouraged because of the different clinical implications of each result.

Since the exact target antigen(s) of atypical P-ANCA

has not been identified, there are currently no sensitive and specific solid-phase assays available to screen for these antibodies. IIF is the only widespread method to detect the antibodies; however it is technically demanding, subjective, and requires experienced observers for good interpretation. Joossens *et al*[10] evaluated the interassay and interobserver variability in the detection of UC-associated atypical P-ANCA comparing four different commercially available assays. Their results confirmed an earlier observation reporting inter-laboratory variability[11]. Not all ANCA assays are suitable for the detection of the anti-neutrophil cytoplasmic antibodies in IBD patients. The differences among the commercially available substrates are remarkable and probably result from differences in cell preparation, fixation methodologies, and conjugates. In addition to substrate differences, ANCA determinations and titer assignment are subjective and are highly dependent on the expertise of the observer. Furthermore, unlike the Consensus Recommendations for the vasculitis-associated ANCAs, there are no clear guidelines for immunofluorescence detection and interpretation of atypical P-ANCA patterns. Consequently, different laboratories may each observe the same pattern (i.e. the test performs consistently), but interpret the pattern differently.

An alternative methodology for the identification of the atypical P-ANCA reactivity developed by Targan and associates, uses a 3-step process that includes ELISA analysis, IIF assay on methanol-fixed neutrophils, followed by another IIF testing on deoxyribonuclease (DNase)-treated neutrophils. DNase-sensitive P-ANCA (i.e. not detectable on DNase-treated neutrophils) is present in the sera of 60% to 80% of the patients with UC and approximately 10% to 30% of patients with CD. In approximately 70% of UC sera, there is ablation of the P-ANCA pattern and the antigen recognition after DNase digestion of substrate cells[12]. This suggests that the epitope recognized by the UC-associated atypical P-ANCA is a protein-DNA complex or that the presence of intact DNA is necessary for maintaining the integrity of the epitope[4]. In up to 30% of the sera, there is conversion to homogeneous cytoplasmic staining, while in 3% of the sera the P-ANCA pattern was retained after DNase treatment of the substrate.

The overall specificity of the atypical P-ANCA is 84%-95%, sensitivity is 48%-63%, positive predictive value (PPV) is 69%, and negative predictive value (NPV) is 89%[5].

Anti-Saccharomyces cerevisiae antibodies

Anti-*Saccharomyces cerevisiae* antibodies (ASCA) are antibodies directed primarily against a 200 kDa-phosphopeptidomannan cell wall component of the common baker's or brewers yeast' *Saccharomyces (S.) cerevisiae*[13]. ASCA reactivity could be a result of cross-reacting antibodies to antigens found in a non-yeast organism and has not yet been identified[14,15]. Mannose is not only found in yeast but also in mycobacteria and other microorganisms[16]. Both IgA and IgG antibodies are formed. Separate and polyvalent ELISA configurations are available for ASCA IgG and IgA detection. ASCA are more frequently found in CD patients (50%-80%) compared to patients with UC (2%-14%) and to normal

healthy subjects (1%-7%)[17,18]. Approximately two-thirds of the CD patients with ASCA IgG are also positive for ASCA IgA, but 0% to 19% of the patients have only ASCA IgA antibodies. This suggests that both ASCA IgG and IgA antibodies should be measured. In CD, up to 90% specificity has been reported in specimens positive for both ASCA IgG and IgA antibodies, especially when the magnitude of both the IgG and IgA ASCA antibodies is high[19]. Sensitivity of ASCA testing ranges from 41%-76%, PPV 88% and NPV 68%[20].

ASCA IgG and IgA levels in CD patients are highly variable[19]. The prevalence of ASCA is much higher in cases of sporadic CD and in families with only CD (63%) compared to families with both CD and UC (33%). The familial trait to ASCA is obvious, but it is questionable whether this is due to the genetic background or environmental agents effect in childhood predisposing to the disease susceptibility.

A comparative study revealed a wide range in sensitivities and specificities among four assays, mainly as a consequence of the cutoff values chosen. Sensitivity was inversely related to specificity and PPV. Results correlated well overall and the different ROC curves showed good agreement[21].

Newly discovered serologic markers

Anti-OmpC antibody is directed against the outer membrane porin C transport protein of the *E. coli*. The detection of the IgA antibody is done with ELISA. Anti-OmpC has been reported in 55% of CD patients[22], but in children and young adults it was only reported 24%[23]. The prevalence of anti-OmpC was insignificant in UC patients and in healthy subjects (5%-11% and 5%, respectively). Anti-OmpC may be of value to aid diagnosis of ASCA negative CD patients. The prevalence of anti-OmpC among ASCA negative patients is 5%-15%.

A fragment of bacterial DNA (I2), a homolog of the tetR bacterial transcriptional factor family, has been identified from lamina propria mononuclear cells in active CD and shown to be associated with *Pseudomonas fluorescens*[24,25]. Anti-I2 antibody IgA has been detected by ELISA in IBD patients with a seroprevalance of 54% in CD and 10% in UC. Anti-I2 antibody was also found in patients with other inflammatory enteritis (19%) and also in healthy subjects (4%)[5].

Serologic expression cloning was used by Lodes *et al* to identify commensal bacterial proteins in colitic mice. The dominant antigens were found to be flagellins. Strong B-cell and CD4+ T-cell responses were observed against one of these flagellins (anti-CBir1). Colitis was induced when the T-cell line specific for CBir1 was transferred into naive severe combined immunodeficient mice. Approximately 50% of patients with CD had IgG serum reactivity to CBir1 *versus* 6% of UC patients and 8% of healthy subjects. CBir1 is the first bacterial antigen to induce colitis in animal models of IBD and also leads to a pathological immune response in IBD patients[26]. Among the population of CD patients positive for atypical P-ANCA, but who do not react to other known antigens, 40%-44% are positive for anti-CBir1 whereas the antibody has only been found in 4% of atypical P-ANCA positive

UC patients. Serum responses to CBir1 may be of help in differentiation between atypical P-ANCA positive CD and UC patients independently of ASCA[27].

Anti-pancreatic antibodies (PAB) are directed against the exocrine pancreatic tissue. The exact target antigen(s) however, has not yet been identified. The detection of PAB is done by IIF on human pancreas substrate. The reported prevalence of PAB is approximately 30% in CD patients compared to 2%-6% of UC patients and 0%-2% of healthy subjects[28]. The relevance of PAB in the pathogenesis of CD is unclear and whether the presence of PAB identifies a CD subgroup also remains to be determined[29].

Patients with CD express antibodies to cell wall carbohydrate epitopes found in different pathogenic bacteria and fungi. Using a glycan array (GlycoChip) and ELISA, anti-glycan antibodies have been found in CD patients including anti-laminaribioside carbohydrate antibody (ALCA) (18%-38%), anti-chitobioside carbohydrate antibody (ACCA) (21%-36%), and anti-mannobioside carbohydrate antibody (AMCA) (28%)[30,31]. Importantly, 24%-44% of the CD patients found ASCA negative in one study were positive for one or more of the anti-glycan antibodies. Patients with CD who were positive for at least one of ALCA, ACCA, or gASCA (very similar to conventional ASCA) could be differentiated from UC patients, with 77% sensitivity and more than 90% specificity. PPV and NPV was 91% and 77%, respectively. When the same criteria were applied to differentiation of CD from control patients, the specificity fell to 70.3%[30]. As one might expect, combination of 2 or more antiglycan antibodies resulted in a higher specificity and PPV in differentiation of CD from UC, but with loss of sensitivity, NPV, and efficiency. These data do not show a great increase in the sensitivity and specifity by the glycan assays. The low correlation between the presence of antibodies against mannan, laminaribioside, and chitobioside suggests that the antigens responsible for these antiglycan antibodies are directed against different microorganisms.

Prevalence of different serologic markers in IBD and their association with the disease phenotype is summarized in Table 1.

DIAGNOSTIC VALUE OF THE SEROLOGIC MARKERS IN IBD

The role of atypical P-ANCA and ASCA as diagnostic markers for IBD appears to be limited because of their moderate sensitivity and presence in other conditions. Atypical P-ANCA can also be observed in other colitis, e.g. collagenous or eosinophilc colitis and in various autoimmune liver diseases such as AIH and PSC[32,33]. ASCA has been found in AIH (20%) and gastrointestinal disorders such as celiac disease[34].

The combination of atypical P-ANCA and ASCA however, may be of help in patients in whom distinction between CD and UC is not obvious with the classic diagnostic tools (patient history, radiologic examination, endoscopy and biopsy). The ASCA+/atypical P-ANCA- serologic pattern is mainly characteristic of CD, while the

Table 1 Prevalence of different serologic markers in IBD and their association with disease phenotype

	Crohn's disease (%)	Ulcerative colitis (%)	Healthy subjects (%)	Clinical significance
Atypical P-ANCA	2-28	45-82	1-7	Assists in differentiation between CD and UC: Atypical P-ANCA$^+$/ASCA$^-$: UC Atypical P-ANCA$^-$/ASCA$^+$: CD CD: ASCA$^+$: ileal involvement, complicated disease course, early need for surgery
ASCA	41-76	5-15	5	Atypical P-ANCA$^+$: left sided colitis, good therapeutical response, uncomplicated disease course UC: Atypical P-ANCA$^+$: severe left sided colitis, refractory to medical therapy, early need for surgery
Anti-OmpC (IgA)	24-55	5-11	5	Identify ASCA$^-$ CD patients Penetrating disease Faster disease progression Early need for surgery
Anti-I2 (IgA)	54	10	4	Inflammatory enteritis (19%) Stricturing form Early need for surgery
Anti-CBir1 (IgG)	50	6	8	Flagellin (CBir1) induce colitis in animal models of IBD Leads to a pathological immune response in IBD patients Differentiation between atypical P-ANCA$^+$ CD and UC Small bowel involvement Penetrating and stenosing form
Antiglycan antibodies (ALCA ACCA)	36	< 10	0	44% in ASCA- patients ALCA-penetrating; ACCA-stenosing form (small differences)
PAB (IIF)	27-39	2-6	0-2	High specificity, low sensitivity Significance? Distinct CD subgroup?

ASCA$^-$/atypical P-ANCA$^+$ is characteristic of UC. Several independent studies found that these combinations had sensitivities of from 30% to 64%, specificity more than 90%, and PPV from 77% to 96%[12,17,18,35,36].

It must be emphasized that neither ASCA, nor atypical P-ANCA negativity rules out IBD. Similarly, the presence of these antibodies does not confirm the diagnosis of IBD.

Serologic evaluation may be of help in patients with indeterminate colitis (IC) to increase the diagnostic accuracy. Ninety-seven patients with IC were enrolled, analyzed for atypical P-ANCA and ASCA, and followed up prospectively in a multicentre study of Joosens *et al*. After the 1-year follow-up, a definitive diagnosis was reached in 31 of 97 patients (37%). In IC patients, ASCA$^+$/atypical P-ANCA$^-$ results correlated with CD in 80%, whereas ASCA$^-$/atypical P-ANCA$^+$ correlated with UC in 63%. The remaining ASCA$^-$/atypical ANCA$^+$ patients were eventually determined to be CD, but clinically showed a UC-like CD phenotype. Remarkably, during the 9.9 year follow-up, 48.5% of the patients did not show antibodies against ASCA or atypical P-ANCA. In 85% of these seronegative patients the diagnosis remained indeterminate. In contrast, 48% of the seropositive patients became CD or UC on follow-up[37]. Adding anti-OmpC and anti-I2 to the serologic panel in patients with IC did not add diagnostic clarification[38].

Several groups have studied whether atypical P-ANCA and ASCA are preclinical markers of IBD in families. Some studies[39,40] showed that presence of atypical P-ANCA occurred frequently in healthy first-degree relatives of UC patients, whereas other studies were not able to confirm this observation[41,42]. ASCA positivity was obviously found at a higher rate in unaffected first-degree relatives of CD patients than in the general population (20%-25% *vs* 5%)[43,44]. Further studies are necessary to clarify whether the unaffected, but ASCA positive, family members face an increased risk of disease development.

Israeli *et al*[45] demonstrated that the presence of ASCA and atypical P-ANCA in healthy subjects can predict for IBD before the emergence of overt clinical manifestations. Serum samples were obtained systematically and stored from 5% of all military recruits. ASCA were detected in 31% of CD patients before clinical diagnosis. The mean interval between ASCA detection and diagnosis was 38 mo. There was no ASCA positivity in control population. Atypical P-ANCA was present in 25% of patients with available sera before the diagnosis of UC. None of their 24 matched controls were positive.

ASSOCIATION WITH DISEASE PHENOTYPES AND PROGRESSION

The occurrence of atypical P-ANCA in UC is associated with a characteristic clinical appearance and represents a distinct subgroup which is often characterized by specific HLA markers. These patients have a higher probability to develop a severe left-sided ulcerative colitis, which is more resistant to treatment than the usual case. The disease has a more aggressive course requiring surgery earlier[47]. Some authors suggest that pouchitis develops more frequently after ileal pouch anastomosis[48], whereas others were not able to confirm this observation. The presence of

atypical P-ANCA identifies a subgroup of CD patients characterized by UC-like colitis; the inflammation usually involves the left side of the colon and the response to therapy is generally good. The atypical P-ANCA in CD patients associated with later age of onset and a relative decreased incidence of complications such as stricture and/or perforation[49-51].

Phenotype and the disease course of CD are heavily dependent on the presence and extent of serologic responses against various microbial antigens. In patients with an ASCA+ (IgG and/or IgA)/atypical P-ANCA- phenotype, small bowel involvement (with or without colonic disease) is more typical than the pure colonic disease (68%-76% vs 34%-46%)[18,51,52]. ASCA positivity predicts a more aggressive disease course with a higher rate of complications. ASCAs have been associated with stricturing (70%) and penetrating (51%) type of disease as opposed to the inflammatory one (14%) and a higher risk of small bowel resection[46,49,53]. Several studies suggest that ASCA positivity is associated with an earlier onset of disease[16,48]. ASCA IgA positivity in children may represent a higher risk for relapses [OR 2.9 (95% CI 1.33-6.33)][54].

The presence of anti-OmpC in adult CD patients is associated with an increased prevalence of the penetrating form only[21,49,50], while in children both the penetrating and stenosing forms[55] are more frequent. Moreover, antibody positivity may lead to a more aggressive course of disease and a higher risk for surgical interventions.

Like ASCA and anti-OmpC, anti-I2 also appears to be associated with an increased risk for complications in adult CD patients. It is an independent risk factor for the development of the stenosing form and the need for surgical interventions[21,49,50].

Recent research has shown that the anti-CBir1 antibody is associated with ileal involvement in adult CD patients independent of other serologic markers, and it predisposes to the development of both stenosing and penetrating forms[26].

Among the anti-glycan antibodies in CD, ALCA is more often positive in the penetrating form (34% vs 25%) and ACCA in the stenosing one (29% vs 18%) when compared to the inflammatory type; although, the differences are small. No correlation was found between the anti-glycan positivity and the need for small-bowel resections[30].

The number of antibodies produced against microbial antigens in CD shows a positive correlation with the severity of the disease course. Mow et al[50] analyzed 303 patients retrospectively and found that simultaneous presence of 3 antibodies (ASCA, anti-OmpC and anti-I2) resulted in an increased risk of complications [stenosing form (72% vs 23%), penetrating form (58.7% vs 27.9%) and need for surgical intervention (72% vs 23%)], as compared to the seronegative group. When all three antibodies were present, the OR was 8.6 (95% CI 4.0-18.9). In addition to qualitative correlations, quantitative correlations with serologic responses are also present. Patients expressing serologic markers at high titers are more likely to have complicated small bowel CD. In a prospective pediatric cohort (n = 196), Dubinsky et al[52], as in a related study by Mow et al[50], found that the presence

and magnitude of immune responses to microbial antigens (ASCA, anti-OmpC, anti-I2 and anti-CBir1) were significantly associated with more aggressive disease phenotype. The risk of developing penetrating and/or stricturing CD was increased 11-fold in those individuals with immune responses to all four microbial antigens compared to seronegative cases [95% CI (1.5-80.4)]. Moreover, they demonstrated that the time to develop a disease complication during the 18 mo of follow-up period was significantly faster in those children who had a serologic response against at least one antigen. There is a difference between the cohort studies performed in children and adults indicating differences as to which immune response has the greatest effect on the course of the disease in children and adults. The reason for this difference is not yet understood.

An elevated titer of several antiglycan antibodies also predispose to the development of complicated ileal CD[30]. In patients positive for more than 2 anti-glycan antibodies (ALCA, ACCA, gASCA), ileal involvement can be seen in 93% of the cases, as compared to seronegative patients (60%) [OR 9.0; 95% CI (3.3-24.5)]. High ALCA titers seem to be correlated with small bowel involvement and the development of stenosing and penetrating disease forms. ACCA titers, on the other hand, demonstrated no such associations.

One should be aware that really striking differences in serologic response are demonstrated only in a minority of patients. About 1/4 of the patients are positive for several antibodies and have markedly elevated antibody titers at the same time. The proportion of seronegative patients, or patients being positive for only 1 antigen with a low antibody titer, is about the same. The remaining 50% of all CD patients have an intermediate phenotype based on the serologic assessments. The aim is to find new serologic markers with which we shall be able to identify certain homogenous groups of patients in this grey zone regarding disease progression and response to therapy[21,30].

SEROLOGICAL MARKERS IN THE FOLLOW-UP AND TREATMENT OF IBD

In patients with UC, no correlation was found between the presence and titer of atypical P-ANCA and the activity of the disease. The titer of atypical P-ANCA remains unchanged even after a colectomy[45]. Similarly, the presence of ASCA in CD patients is relatively constant during the course of the disease and seems to be independent of the disease activity[45,48,51]. As a consequence, neither atypical P-ANCA, nor ASCA is suitable for monitoring the disease. The ALCA and ACCA titers also seem to be independent of disease activity[30]. The prevalence of ASCA, anti-I2, anti-OmpC, and the presence of multiple serologic responses are more frequent when the disease persists for a long time[49,56].

Landers et al found that following anti-TNF-α treatment the prevalence and titer of various antibodies (ASCA, atypical P-ANCA, anti-I2 and anti-OmpC) remained unchanged in the majority of patients[30]. Mesalamine treatment also leaves the ASCA level unchanged in active CD patients[57]. ASCA positivity

remains even after steroid treatment, but the antibody titer decreases[58].

The role of the serologic response in the prediction of therapeutical effectiveness is yet to be determined. A Belgian study involving 279 CD patients failed to find any correlation between the atypical P-ANCA or ASCA positivity and the rate of response of patients given anti-TNF-α treatment. The investigators observed a generally poorer responsiveness in the case of atypical P-ANCA[+]/ASCA[-] status, but the difference was not significant[59].

Patients exhibiting serologic responses against various microbial antigens (OmpC and I2) should expect a higher remission rate if the budesonide treatment was supplemented with ciprofloxacin and metronidazole, while in anti-OmpC/I2 seronegative group budesonide treatment alone proved to be more effective[60]. The study brings up the possibility that certain antibiotics are more effectively used in those CD patients who present a marked immunologic response against microbial antigens. This group of patients may be the one that can be most effectively treated by manipulating the bacterial flora.

MUTATIONS OF THE SEROLOGIC MARKERS AND RECEPTORS TAKING PART IN INNATE IMMUNITY

Genetic heterogeneity may be responsible for the differences found in the serologic response. Literature is split regarding the possible correlation between antibody production in patients with CD and the NOD2/CARD 15 status. Several studies found the serologic response (atypical P-ANCA, anti-I2, anti-OmpC, ASCA IgG/IgA) to be independent of the NOD2/CARD 15 status[50,53]. A Belgian workgroup, on the other hand, confirmed the proposed association in a large (n = 913) cohort of patients. When more than 1 NOD2/CARD 15 mutation was present, the investigators found the rate of gASCA positivity and its titer to be significantly higher. Moreover, they found a positive correlation between the number of mutations and the prevalence of gASCA and ALCA, which may indicate a gene dose effect[61].

Investigating the association of the serologic response with the toll-like receptor (TLR)-4 gene D299G (Asp299Gly) polymorphism led to results in contrast to those found with the NOD2/CARD 15 assessments. If the patient had a variant TLR-4 genotype, the rate of ACCA positivity was less frequent as compared to the wild type, which again suggests a gene dose effect. Polymorphism may also play a role in the development of serologic responses against the Gram-negative *E. coli* membrane protein. The Belgian workgroup also found a correlation between anti-Omp positivity and TLR4 gene polymorphism in patients with UC (n = 272)[59]. Anti-Omp positivity was significantly less frequent among patients with a TLR4 variant genotype and prevalence of the antibody showed an inverse correlation with the number of the variants[58].

It must be mentioned that the immune response against microbial antigens seems to be more closely correlated with disease phenotype and the frequency of complications in CD than the known predisposing genetic factors.

SEROLOGIC MARKERS IN THE PATHOPHYSIOLOGY OF IBD

The real importance of the antibodies produced against various microbial and autoantigens is still unclear. A fundamental question that remains to be answered is whether these antibodies play a role in the immunopathogenesis of IBD, or their appearance is merely a consequence of the inflamed, leaky bowel mucosa. Several studies suggest that the main reason for the antibody production is loss of the immune tolerance, rather than increased bowel permeability[48,62]. Clinical studies could not find any correlation between the serologic response and bowel permeability in CD patients, suggesting that the presence of different serologic markers is not an epiphenomenon related to disease activity[21,45,48,51].

Lindbergh *et al*[63] demonstrated that CD was associated with a high serologic response against yeast and mannose, but no antibodies were produced against food antigens. Konrad *et al*[64] found strong and specific lymphocyte reaction against mannose in ASCA positive CD patients, but not against the nutritional antigen, ovalbumin. Both studies concluded that the serologic response in CD is a highly selective process against certain antigens and not a generalized immune hyperreactivity against the intestinal content.

Dubinsky *et al*[52] reported that the immune response against bacteria is not a consequence of the transmural penetration, since it develops earlier. It remains, however, an open question as to what was the extent of the immune response before the onset of the complications in the symptom-free patients, where no serologic assessments were performed due to the lack of clinical signs. Results of this study coincide with earlier observations that the presence of serologic response in a given patient does not change during the course of disease.

The currently accepted theory for the etiopathogenesis of IBD suggests that susceptibility to the disease, the clinical manifestations, and the progression depend equally on genetic factors, impairment of immune regulation, and environmental effects. The chronic inflammation of the intestinal mucosa and the related systemic reactions in IBD are consequences of an exaggerated immune response against the endogenous gut flora.

When the immune and/or barrier function of the bowel mucosa are genetically impaired, certain environmental factors may easily initiate a pathologic process. Animal models[65-67] highlight the importance of the interaction between host and its intraluminal bacteria. In the presence of a particular genetic defect, not every member of the commensal bacterial flora is able to induce pathologic immune response and the extent of the serologic reaction-and thus the clinical appearance of the disease-may differ. A higher rate of antibody production may reflect the extent of loss of tolerance against the various microbial antigens. A clinical interpretation of this observation may be that the effect of bacteria on the

prevalence and extent of the inflammatory reaction may affect the course of disease. Loss of immune tolerance in CD develops against targeted microbial and autoantigens and is not a global process[52].

CONCLUSION

ASCA and atypical P-ANCA remain the best-characterized markers in IBD. Unlike ASCA assays, which are generally ELISA tests and both simple to run and well-standardized, atypical P-ANCA testing is dependent on experienced personnel for both running and interpreting the test results. Results of the various assays used for the detection of atypical P-ANCA may differ significantly from each other and must therefore be compared very carefully. Individually ASCA and atypical P-ANCA tests have moderate sensitivity and specificity. Atypical P-ANCA and ASCA cannot be used for monitoring, because the antibody titers are relatively stable and do not correlate with disease activity.

Assessing both ASCA and atypical P-ANCA reactivity allows better differentiation of CD from UC and from non-CD than using the individual tests alone. The ASCA$^+$/atypical P-ANCA$^-$ phenotype is characteristic of CD, while the ASCA$^-$/atypical P-ANCA$^+$ phenotype is seen primarily in UC. Viewed together, the two assays offer a differential diagnostic tool, which may be particularly helpful in those cases when the diagnosis of CD or UC cannot be safely established using conventional investigation methods (medical history, radiological assessments, endoscopy and biopsy). These markers can help in the assessment of about half of the patients in the indeterminate colitis (CD or UC) category. In Crohn's disease ASCA positivity carries a higher chance of a complicated disease behavior and the need for early surgical intervention. In UC the presence of atypical P-ANCA one can expect a dominantly left-sided disease, which is often severe and resistant to therapy, with a high risk of early surgical intervention.

Newer markers derived from various microbial inhabitants of the gut, such as Omp, I2, and CBir1, as well as various glycan markers offer new ways to stratify patients into serologic subgroups. The cumulative presence and extent of the serologic response against these various markers may act as prognostic indicators of the severity and behavior of the ileal disease. Although the prevalence of antibodies is higher in healthy relatives of IBD patients than in the control population, their role as subclinical markers is yet to be established.

There is considerable overlap of the reactivity of many of the new serological markers and additional studies to more fully understand the basis for their development as well as their clinical significance are required. Addition of these, as well as yet to be discovered new markers, to the serologic IBD diagnostic algorithm will likely result in incremental increases in sensitivity. Increases in sensitivity however, can often be accompanied by reductions in specificity and this outcome must be carefully assessed and recognized. Evolution of effective serological test panels will involve shifting through the various markers to arrive at optimal diagnostic utility balanced with practical economic realities.

We have made significant progress in understanding the clinical features associated with various serologic markers in IBD. The ongoing challenge is how to best utilize these new assays to provide clinically relevant information in a cost-effective manner. Assembly of logical panels of serologic markers to identify patients at increased risk of more severe disease and who may benefit from early intensive monitoring and therapy to improve long-term outcome is a primary practical goal. Further prospective clinical trials will be needed to determine the evolving role and practical clinical importance of serologic assessments in IBD.

REFERENCES

1   **Savige J**, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R, Pusey C, Pollock W, Trevisin M, Wiik A, Wong R. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. *Am J Clin Pathol* 2003; **120**: 312-318

2   **Terjung B**, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. *Gastroenterology* 2000; **119**: 310-322

3   **Saxon A**, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. *J Allergy Clin Immunol* 1990; **86**: 202-210

4   **Rump JA**, Scholmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Ludemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. *Immunobiology* 1990; **181**: 406-413

5   **Bossuyt X**. Serologic markers in inflammatory bowel disease. *Clin Chem* 2006; **52**: 171-181

6   **Terjung B**, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol* 2001; **15**: 629-642

7   **Terjung B**, Bogsch F, Klein R, Sohne J, Reichel C, Wasmuth JC, Beuers U, Sauerbruch T, Spengler U. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. *Eur J Med Res* 2004; **9**: 439-448

8   **Eggena M**, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon LK, Braun J. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. *J Autoimmun* 2000; **14**: 83-97

9   **Terjung B**, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. *Clin Exp Immunol* 2001; **126**: 37-46

10 **Joossens S**, Daperno M, Shums Z, Van Steen K, Goeken JA, Trapani C, Norman GL, Godefridis G, Claessens G, Pera A, Pierik M, Vermeire S, Rutgeerts P, Bossuyt X. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. *Clin Chem* 2004; **50**: 1422-1425

11 **Sandborn WJ**, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. *Inflamm Bowel Dis* 2001; **7**: 192-201

12 **Vidrich A**, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. *J Clin Immunol* 1995; **15**:

293-299

13 **Main J**, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. *BMJ* 1988; **297**: 1105-1106

14 **Heelan BT**, Allan S, Barnes RM. Identification of a 200-kDa glycoprotein antigen of Saccharomyces cerevisiae. *Immunol Lett* 1991; **28**: 181-185

15 **Sendid B**, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, Lucidarme D, Camus D, Poulain D. Specific antibody response to oligomannosidic epitopes in Crohn's disease. *Clin Diagn Lab Immunol* 1996; **3**: 219-226

16 **Nakamura RM**, Matsutani M, Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. *Clin Chim Acta* 2003; **335**: 19-20

17 **Quinton JF**, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. *Gut* 1998; **42**: 788-791

18 **Peeters M**, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. *Am J Gastroenterol* 2001; **96**: 730-734

19 **Norman GL**. Anti- Saccharomyces cerevisiae antibodies in inflammatory bowel disease. *Clin Applied Immunol Rev* 2001; **2**: 45-63

20 **Vermeire S**, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. *Gastroenterology* 2001; **120**: 827-833

21 **Vermeire S**, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. *Gastroenterology* 2001; **120**: 827-833

22 **Landers CJ**, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. *Gastroenterology* 2002; **123**: 689-699

23 **Zholudev A**, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. *Am J Gastroenterol* 2004; **99**: 2235-2241

24 **Sutton CL**, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J. Identification of a novel bacterial sequence associated with Crohn's disease. *Gastroenterology* 2000; **119**: 23-31

25 **Wei B**, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. *Infect Immun* 2002; **70**: 6567-6575

26 **Lodes MJ**, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 2004; **113**: 1296-1306

27 **Targan SR**, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterology* 2005; **128**: 2020-2028

28 **Lawrance IC**, Hall A, Leong R, Pearce C, Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. *Inflamm Bowel Dis* 2005; **11**: 890-897

29 **Stocker W**, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, Jantschek G, Scriba PC. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1987; **139**: 41-52

30 **Ferrante M**, Pierik M, Henckaerts L, Dotan N, Norman GL, Altstock RT, Dotan I, Shums Z, Schooler B, Claes K, Van Schuerbeek V, Van Assche G, Rutgeerts P, Vermeire S: A panel of serological antibodies (gASCA, OMP, ACCA, ALCA and AMCA) predicts complicated disease course and surgery in Crohn's disease. *Am J Gastroenterol* 2006; **A**: 129

31 **Dotan I**, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. *Gastroenterology* 2006; **131**: 366-378

32 **Czaja AJ**, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. *Dig Dis Sci* 2004; **49**: 611-618

33 **Reddy KR**, Colombel JF, Poulain D, Krawitt EL. Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. *Am J Gastroenterol* 2001; **96**: 252-253

34 **Vernier G**, Sendid B, Poulain D, Colombel JF. Relevance of serologic studies in inflammatory bowel disease. *Curr Gastroenterol Rep* 2004; **6**: 482-487

35 **Linskens RK**, Mallant-Hent RC, Groothuismink ZM, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, von Blomberg BM, Meuwissen SG. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. *Eur J Gastroenterol Hepatol* 2002; **14**: 1013-1018

36 **Koutroubakis IE**, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, Maniatis AN, Kouroumalis EA. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. *Am J Gastroenterol* 2001; **96**: 449-454

37 **Joossens S**, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF. The value of serologic markers in indeterminate colitis: a prospective follow-up study. *Gastroenterology* 2002; **122**: 1242-1247

38 **Joossens S**, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts P, Reinisch W. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. *Gut* 2006; **55**: 1667-1669

39 **Seibold F**, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. *Gastroenterology* 1994; **107**: 532-536

40 **Shanahan F**, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, Landers CJ, Targan SR. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. *Gastroenterology* 1992; **103**: 456-461

41 **Lee JC**, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. *Gastroenterology* 1995; **108**: 428-433

42 **Folwaczny C**, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. *Scand J Gastroenterol* 1998; **33**: 523-528

43 **Sendid B**, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, Poulain D, Colombel JF. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. *Am J Gastroenterol* 1998; **93**: 1306-1310

44 **Seibold F**, Stich O, Hufnagl R, Kamil S, Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. *Scand J Gastroenterol* 2001; **36**: 196-201

45 **Israeli E**, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. *Gut* 2005; **54**: 1232-1236

46 **Sandborn WJ**, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. *Mayo Clin Proc* 1996; **71**: 431-436

47 **Sandborn WJ**, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic

pouchitis after ileal pouch-anal anastomosis. *Am J Gastroenterol* 1995; **90**: 740-747

48 **Vasiliauskas EA**, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. *Gastroenterology* 1996; **110**: 1810-1819

49 **Vasiliauskas EA**, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. *Gut* 2000; **47**: 487-496

50 **Klebl FH**, Bataille F, Bertea CR, Herfarth H, Hofstadter F, Scholmerich J, Rogler G. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. *Inflamm Bowel Dis* 2003; **9**: 302-307

51 **Vermeire S**, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, Bossuyt X, Geypens B, Rutgeerts P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. *Inflamm Bowel Dis* 2001; **7**: 8-15

52 **Walker LJ**, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. *Clin Exp Immunol* 2004; **135**: 490-496

53 **Mow WS**, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterology* 2004; **126**: 414-424

54 **Desir B**, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. *Clin Gastroenterol Hepatol* 2004; **2**: 139-146

55 **Dubinsky MC**, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. *Am J Gastroenterol* 2006; **101**: 360-367

56 **Arnott ID**, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. *Am J Gastroenterol* 2004; **99**: 2376-2384

57 **Oshitani N**, Hato F, Matsumoto T, Jinno Y, Sawa Y, Hara J, Nakamura S, Seki S, Arakawa T, Kitano A, Kitagawa S, Kuroki

T. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease. *J Gastroenterol Hepatol* 2000; **15**: 1400-1403

58 **Teml A**, Kratzer V, Schneider B, Lochs H, Norman GL, Gangl A, Vogelsang H, Reinisch W. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. *Am J Gastroenterol* 2003; **98**: 2226-2231

59 **Esters N**, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. *Am J Gastroenterol* 2002; **97**: 1458-1462

60 **Mow WS**, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, Greenberg GR, Targan SR. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. *Dig Dis Sci* 2004; **49**: 1280-1286

61 **Henckaerts L**, Pierik M, Claes K, Ferrante M, Vanschuerbeek N, Dotan N, Norman GL, Altstock RT, Dotan I, Schooler B, Shums Z, Rutgeerts P, Vermeire S. Mutations in innate immune receptors modulate the serologic response to microbial antigens in patients with inflammatory bowel disease. *Am J Gastroenterol* 2006; **A**: T1974

62 **Harrer M**, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, Norman GL, Gangl A, Vogelsang H. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? *Eur J Gastroenterol Hepatol* 2003; **15**: 1281-1285

63 **Lindberg E**, Magnusson KE, Tysk C, Jarnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. *Gut* 1992; **33**: 909-913

64 **Konrad A**, Rutten C, Flogerzi B, Styner M, Goke B, Seibold F. Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. *Inflamm Bowel Dis* 2004; **10**: 97-105

65 **Rath HC**, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. *Gastroenterology* 1999; **116**: 310-319

66 **Rath HC**, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. *Infect Immun* 1999; **67**: 2969-2974

67 **Kim SC**, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. *Gastroenterology* 2005; **128**: 891-906